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Tumor-Suppressor Gene Underlies Myhre Syndrome
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Myhre syndrome is a developmental disorder characterized by reduced growth, generalized muscular hypertrophy, facial dysmorphism,
deafness, cognitive deficits, joint stiffness, and skeletal anomalies. Here, by performing exome sequencing of a single affected individual
and coupling the results to a hypothesis-driven filtering strategy, we establish that heterozygousmutations in SMAD4, which encodes for
a transducer mediating transforming growth factor b and bone morphogenetic protein signaling branches, underlie this rare Mendelian
trait. Two recurrent de novo SMAD4 mutations were identified in eight unrelated subjects. Both mutations were missense changes
altering Ile500 within the evolutionary conserved MAD homology 2 domain, a well knownmutational hot spot in malignancies. Struc-
tural analyses suggest that the substituted residues are likely to perturb the binding properties of the mutant protein to signaling part-
ners. Although SMAD4 has been established as a tumor suppressor gene somatically mutated in pancreatic, gastrointestinal, and skin
cancers, and germline loss-of-function lesions and deletions of this gene have been documented to cause disorders that predispose indi-
viduals to gastrointestinal cancer and vascular dysplasias, the present report identifies a previously unrecognized class of mutations in
the gene with profound impact on development and growth.Myhre syndrome (MIM 139210) is the eponym for the
disorder originally described 30 years ago in two unrelated
males exhibiting distinctive dysmorphic features, short
stature, generalized muscular hypertrophy, cryptorchi-
dism, limitation of joints, deafness, and intellectual
disability.1 Myhre syndrome is a rare condition with less
than 30 affected individuals, mostly males, reported to
date.2–8 Based on the available records, cardinal features
of Myhre syndrome include reduced growth, generalized
muscular hypertrophy, variable cognitive deficits, a recog-
nizable pattern of facial features (i.e., narrow palpebral
fissures, midface hypoplasia, a small mouth with a thin
upper lip, and prognathism), and skeletal anomalies (i.e.,
thick skull bones, platispondyly, large vertebral pedicles,
broad ribs, hypoplastic iliac wings, and brachydactyly),
joint stiffness, and deafness. Additional recurrent features
include a cleft lip and/or palate, congenital heart defects,
stiff skin, cryptorchidism, hypertension, and ocular
defects. Myhre syndrome has clinical overlap with growth
retardation, ocular abnormalities, microcephaly, brachy-
dactyly, and oligophrenia (GOMBO) syndrome (MIM
233270); laryngotracheal stenosis, progressive, with short
stature and arthropathy syndrome (LAPS) syndrome
(MIM 603391); geleophysic dysplasia (GPHYSD1 [MIM
231050] and GPHYSD2 [MIM 614185]); acromicric
dysplasia (ACMICD [MIM 102370]); Weill-Marchesani
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The Americ608328]); and Moore-Federman syndrome (MIM 127200);
genetic relatedness among these disorders has been sug-
gested.9–11 Although the molecular basis for some of these
clinically related conditions is unknown, increasing
evidence supports the relevant role of transforming growth
factor b (TGFb) signaling dysregulation in the pathogenesis
of GPHYSD, ACMICD, and WMS.12,13 Here, an exome
sequencing-based approach was used to identify similar
to mothers against decapentaplegic (SMAD) family
member 4 (SMAD4 [MIM 600993]), previously known as
mothers against decapentaplegic homolog 4 (Drosophila)
(MADH4), which encodes a protein with a crucial role in
TGFb/bone morphogenetic protein (BMP) signal transduc-
tion, as the gene mutated in Myhre syndrome.
Eight subjects with clinical features fitting Myhre
syndrome were included in the study (Table 1 and
Figure 1A). Clinical data and biological material collection
and storage were attained from the participating families
in accordance with the ethical standards of the institu-
tional review boards (Ospedale ‘‘Bambino Gesu`’’, Rome;
Universita` di Torino, Turin; Arcispedale Santa Maria
Nuova, Reggio Emilia; Ospedale Microcitemico, Cagliari;
Universita` ‘‘Federico II’’, Naples) and after written
informed consent was secured. Genomic DNAwas isolated
from skin fibroblasts, hair bulb cells, peripheral blood
leukocytes, saliva, and/or buccal mucosal epithelial cells
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Table 1. Clinical Features of the Affected Subjects Included in the Study
Features
Subjects
OBG_01 TO_01 TO_02 TO_03 RE_01 NA_01 NA_02 CA_01
Nucleotide substitution 1498A>G 1499T>C 1498A>G 1498A>G 1499T>C 1498A>G 1498A>G 1499T>C
Predicted amino acid
change
Ile500Val Ile500Thr Ile500Val Ile500Val Ile500Thr Ile500Val Ile500Val Ile500Thr
Paternal age at birth
(years)
35 34 38 36 31 33 28 36
Length at birth (centile) n.a. 3rd <3rd 3rd <3rd n.a. n.a. <3rd
Weight at birth (centile) <3rd 3rd <3rd 3rd <3rd <3rd n.a. <3rd
Head circumference at
birth (centile)
n.a. 3rd <3rd n.a. <3rd n.a. n.a. n.a.
Age at examination
(years)
42 13 4.5 26 13 14 34 13
Gender male male female female male male female male
Height (centile) <3rd <3rd <3rd <3rd <3rd <3rd <3rd <3rd
Obesity þ   þ þ þ þ 
Macrocephaly  þ   þ   
Facial Features
Narrow palpebral fissures þ þ þ þ þ þ þ þ
Midfacial hypoplasia þ þ þ þ þ þ þ þ
Short philtrum þ þ þ þ þ þ þ þ
Narrow mouth and/or
thin upper lip
þ þ þ þ þ   þ
Cleft lip and/or palate  þa þb þ    
Prognathism þ þ þ þ þ þ þ þ
Ocular Anomalies
Refractive errors þc þ  þ  þ  
Cataract      n.a.  þ
Hearing loss þd þe þf þe þf þe þe þd
Cognitive impairment mild moderate þg h þg þ þ þ
Autistic behavior      þ  þ
Muscular hypertrophy þ þ þ þ þ þ þ þ
Joint stiffness þ þ þ þ þ þ þ þ
Skeletal Anomalies
Thick calvarium þ þ þ þ þ þ þ þ
Hypoplastic iliac wings þ þ þ þ þ þ þ þ
Platispondyly þ þ þ þ   þ þ
Large vertebral pedicles þ  n.a. þ þ þ þ þ
Fused vertebrae   n.a.     
Broad Ribs  þ  þ þ   þ
Brachycamptodactyly þ þ þ þ þ þ þ þ
Congenital heart defects þi  þj þk þl  þk þm
Cryptorchidism  þ  þ 
Hypertension þ       þ




OBG_01 TO_01 TO_02 TO_03 RE_01 NA_01 NA_02 CA_01
Skin Anomalies
Stiff skin þ þ  þ þ þ þ 
Thick skin  þ  þ þ þ þ þ
Other features  þn þo  þp  þq 
n.a. is used as an abbreviation for data not available. Subjects TO_3 and NA_01 were previously reported by Rulli et al.5 and Titomanlio et al.45
a Unilateral cleft lip.
b Submucous cleft palate.
c Astigmatism.
d Sensorineural deafness.
e Mixed hearing loss.
f Conductive.
g Delayed psychomotor and language development.
h Psychological and behavioral problems.
i Right ventricular hypertrophy.
j Ventricular and atrial septal defects, patent ductus arteriosus.
k Aortic valve stenosis.
l Aortic coarctation.
m Patent ductus arteriosus.
n Benign mesencephalic glioma, fibrous dysplasia of the maxilla.
o Hirschprung disease diagnosed at birth.
p Pericarditis with cardiac tamponade.
q Secondary amennorrea.subtelomeric fluorescence in situ hybridization (FISH)
analyses provided normal results. High-resolution array-
comparative genomic hybridization (CGH) or SNP array
analyses were performed on three out of the eight subjects
and did not disclose any disease-causing genomic rear-
rangement.
Targeted enrichment and parallel sequencing experi-
ments were performed on genomic DNA extracted from
circulating leukocytes of a single affected subject
(OBG_01). After fragment size selection, GS FLX Titanium
adaptors (Roche) were ligated to the sheared genomic frag-
ments to construct a shotgun sequencing library that was
hybridized with a Sequence Capture Human Exome 2.1M
Array v.2 (NimbleGen). Captured fragments were then
amplified through emPCR and sequenced with Titanium
reagents in a two-lane gasket PicoTiterPlate device
(70X75) with a GS FLX instrument (Roche 454). Image
analysis and base calling were performed with the GS
FLX pipeline software (version 2.5.3). Approximately
1.2 Gb of genomic sequence from two GS FLX runs was ob-
tained. The average read length was 380 bp, and fragment
sizes ranged from 40 to 1,100 bp. Sequencing data were
initially processed with the GSMapper software package
v.2.5.3 (Roche), and high-quality sequencing reads were
aligned to the human genome reference sequence (USCS
hg19, GRCh37). Ninety-four percent of sequence reads
mapped to the human reference genome. Targeted
sequence coverage was 98%, and there was an average
sequence depth of 103. Sequence alignment and func-
tional annotation of the identified variants data were ob-
tained with BEDTools v.2.1214 or extracted from reference
databases with batch queries. Variant detection was per-
formed with a combination of stringency parametersThe Americwith the GSMapper software, resulting in the generation
of a high-confidence variants detection gene list of
72,426 variants. Among the 2,946 novel variants (filtered
against the dbSNP build 131 database), 665 changes map-
ped within coding regions. Nonsynonymous and splice-
site variants were further filtered (UniProtKB/Swiss-Prot,
HapMap and in-house exome variants databases) and
stringently aligned to the human genome (BLAST NCBI)
allowing the selection of 185 nonsynonymous and 18
splice-site valid variants. PolyPhen-215 and SIFT16 analyses
predicted a potential deleterious effect on protein structure
and/or function in 40% of those variants.
Based on the evidence that all affected subjects were
born to apparently healthy nonconsanguineous parents,
we considered heterozygosity for a de novo mutation as
the most likely event underlying the trait. This hypothesis
was also supported by advanced paternal age in the
majority of the reported cases as well as in subjects of the
present cohort (Table 1). In Myhre syndrome, the differen-
tial diagnosis usually considers GPHYSD. Based on the
causative link of TGFb signaling to the latter,12,13 we per-
formed a filtering strategy directed to select gene candi-
dates functionally linked to this signaling network. For
this, data mining analyses were performed with the
DAVID17 algorithm, an integrated biological knowledge-
base and analytic tool aimed at systematically extracting
biological meaning from large gene lists. We used the func-
tional annotation table tool to query corresponding
pathway annotation for each gene and selected candidates
whose products were functionally related to TGFb
signaling (Kyoto Encyclopedia of Genes and Genomes
[KEGG] pathway). This approach allowed the identifica-
tion of three genes, i.e., PITX2 (MIM 601542), SMAD4an Journal of Human Genetics 90, 161–169, January 13, 2012 163
Figure 1. A Restricted Spectrum of Germline Missense Mutations in SMAD4 Underlies Myhre Syndrome
(A) Clinical features of representative subjects (from left, OBG_01, TO_01, and TO_02) carrying the heterozygous SMAD4 mutations.
Pictures illustrate the distinctive facial features, muscular build, joint stiffness, camptodactyly, and brachydactyly. Radiographs show
the thickening of the skull bones, vertebrae with large pedicles and irregular endplates, wide ribs, and hypoplastic iliac wings.
(B) The location of Ile500 is shown below the SMAD4 domain structure scheme. SMAD4 comprises an N-terminal MAD homology 1
domain (MH1) connected by a linker to the SMAD4 activation domain (SAD) and the C-terminal MAD homology 2 domain (MH2).
Numbers below the domain structure indicate the amino acid boundaries of those domains. Nonsense (red circle) and truncating
(pink triangle) mutations reported in juvenile polyposis syndrome (JPS) and JPS-hereditary hemorrhagic telangiectasia are shown below
the illustration. The distribution of somatic SMAD4mutations occurring in cancer (blue-filled peaks) is shown above the illustration. The
location of Lys519, which is the residue subject to ubiquination, is also shown.and THBS3 (MIM 18862). Genes harboring novel variants
were also ranked via a text mining algorithm, Ge´nie,18
that evaluates gene function based on analysis of the liter-
ature. By using combinations of terms from the OMIM
clinical synopsis of Myhre syndrome (e.g., short stature,
joint stiffness, muscular hypertrophy, brachydactyly, deaf-
ness, and mental retardation) as biological topics, and a
p value cutoff < 0.005 for the selection specificity of the
abstracts and the false discovery rate for the gene selec-
tions, the Ge´nie algorithm’s evaluation of available
MEDLINE records allowed ranking of candidate genes and
selection of a panel of ten genes (CRB1 [MIM 604210],
EFHC1 [MIM 608815], HSPG2 [MIM 142461],MYH2 [MIM
160740], PKD2 [MIM 173910], PITX2, SETX [MIM164 The American Journal of Human Genetics 90, 161–169, January 1608465], MRE11A [MIM 600814], SMAD4, and USH1C
[MIM 605242]) as significantly linked. Given the crucial
role of SMAD4 in BMP/TGFb signaling, its ubiquitous
expression, and its relevant function in early and late
developmental processes,19 we considered this gene as the
most promising candidate. Sanger sequencing of the
relevant coding exon confirmed heterozygosity for the
c.1498A>G (p.Ile500Val) change in the affected subject,
and sequencing of parental DNAs revealed only reference
alleles, evidence for its de novo origin. STR genotyping
(PowerPlex ESX16 System [Promega]) confirmed paternity.
The defect was documented in the proband’s skin fibro-
blasts as well as hair bulb and buccal mucosal epithelial
cell specimens, strongly arguing against the possibility of3, 2012
Figure 2. Location of Ile500 in the Spatial Structure of the
SMAD3/SMAD4 MH2 Domain Complex
(A) Solvent accessible surface representation of the SMAD4/
SMAD3 MH2 domain complex (Protein Data Bank [PDB] ID codes
1U7F). The SMAD4 monomer is shown in cyan, whereas the two
SMAD3 subunits are colored in yellow and white. The solvent
accessible surface of residues affected by somatic (blue) and germ-
line (magenta) mutations and lesions occurring as both germline
and somatic events (green) are shown. The residue mutated in
Myhre syndrome, Ile500, is shown in red. The red and blue ovals
indicate the location of the loop/helix and helix bundle SMAD4
subdomains, respectively. Orange ovals indicate the position of
the serine residues that are phosphorylated in activated SMAD3.
(B) Ca ribbon trace (PDB ID codes 1U7F) of SMAD4 MH2 domain
(cyan) and those of the two interacting SMAD3 subunits (orange
and gray). Ile500 is represented in space-filling mode (red). Resi-
dues interacting with Ile500 (Arg496, Arg497, Arg502, Glu526,
and His528) are shown as blue sticks. Asp493 (green), which is
important for interdomain interactions, and Lys519 (violet),
which is subject to ubiquination, are also shown. SMAD3 residues
directly contributing to interactions with the evidenced SMAD4
residues (Ser275, Arg279, Glu284, and Arg287) are shown as
yellow sticks, together with the phosphorylated SMAD3 serine
residues (brown). The anion binding site located in proximity of
Ile500, as indicated by the structure of the SMAD4 homotrimer
(pdb code 1DD1), is shown by a yellow sphere. Visualization
and analysis of the molecular structure was performed with the
program UCSF Chimera.46a somatic event (Figure S1, available online). Consistent
with the notion that this SMAD4 de novo change was
the causative mutation, the other confirmed candidate
variants turned out to be inherited from one of the two
healthy parents. These findings strongly pointed to
SMAD4 as the gene mutated in Myhre syndrome.
To confirm the causal involvement of SMAD4 in Myhre
syndrome, the entire coding sequence of the gene
(NM_005359) was scanned for mutations in DNA obtainedThe Americfrom circulating leukocytes from an additional seven unre-
lated affected subjects by direct sequencing with an ABI
Prism 3500 Genetic Analyzers (Applied Biosystems) and
the ABI BigDye Terminator Sequencing Kit v.3.1 (Applied
Biosystems). Primer pairs designed to amplify exons and
their intron boundaries are listed in Table S1. Mutation
analysis identified heterozygous SMAD4 mutations in all
individuals. Among the seven subjects, four shared the
c.1498A>G nucleotide change (p.Ile500Val), whereas the
c.1499T>C change, predicting a different amino acid
substitutions at the same codon (p.Ile500Thr), was identi-
fied in the three remaining individuals (Figure S1). In all
family trios, parental DNA genotyping demonstrated the
de novo origin of each mutation, and STR genotyping
confirmed paternity. Fibroblasts and/or epithelial cells
were available for three of the seven subjects, and
sequencing documented the defect, supporting the germ-
line origin of these changes. Consistent with these find-
ings, the c.1498A>G and c.1499T>C substitutions were
not observed in more than 400 population-matched unaf-
fected individuals scanned by high-resolution melting
analysis and direct sequencing.
The Ile500 residue lies in the MAD homology 2 (MH2)
domain, a region at the C terminus of the protein that is
conserved among SMAD4 orthologs and paralogs (Figures
S2 and S3) and known to represent the mutational hot
spot for somatic and germline lesions occurring in malig-
nancies and cancer-prone disorders (Figure 1B).20 The
MH2 domain mediates interaction with a wide variety of
proteins, provides specificity and selectivity to SMAD func-
tion, and is indispensable for SMAD oligomerization,21
which is required for TGFb/BMP signal transduction. Flow
through this signaling network occurs through ligand-
induced heteromeric receptor complexes consisting of
type I and type II transmembrane serine/threonine recep-
tors that recruit and phosphorylate receptor-regulated
SMADs (R-SMADs), which in turn heterotrimerize with
the common mediator, SMAD4. SMAD complexes then
accumulate into thenucleus to regulate expression of target
genes.22 In the structure of the SMAD4 MH2 domain,
Ile500 is located close to the protein surface, but it is solvent
accessible only for 6% of the residue surface, because it is
surrounded by and interacts with the hydrocarbon part of
the side chains of residues Arg496, Arg497, Arg502,
Glu526, and His528 (Figure 2). With the exception of
Arg496, these residues are highly conserved in SMAD4 or-
thologs and paralogs and constitute a binding site for
anions.23 The solvent-exposed location of this region and
its highly charged character make it a likely candidate for
protein-protein interactions and point to disturbed
SMAD4 binding to signaling partners at this site as the
possible effect promoted by the identified mutations.
The best characterized complexes formed by SMAD4 are
those resulting from its association with SMAD2 (MIM
601366) or SMAD3 (MIM 603109). Biochemical and
crystallographic evidence indicates that these complexes
are trimeric units comprising one SMAD4 and twoan Journal of Human Genetics 90, 161–169, January 13, 2012 165
phosphorylated R-SMAD subunits. The complex is charac-
terized by three nonidentical interfaces, two of which
involve separate solvent-exposed surfaces of the SMAD4
MH2 domain.24 According to the crystal structure of the
SMAD2/SMAD4 and SMAD3/SMAD4 heterotrimeric
complexes,24 Ile500 is located within one of the two
MH2 surfaces involved in R-SMAD binding, and the resi-
dues surrounding it participate directly in the intermolec-
ular interaction. Particularly, Arg497 and Asp493 form
ion pairs with acidic residues of the R-SMAD subunit
(Figure 2B). Although a number of missense mutations
affecting conserved residues of this region (e.g., Asp493),
which were documented or predicted to disrupt SMAD4
homo- and heteromerization, has been identified as
somatic and/or germline lesions in malignancies and
cancer-prone diseases (Catalogue of Somatic Mutations in
Cancer, [COSMIC] and Human Gene Mutation Database
[HGMD]) (Figure 1B and Figure S2), no missense mutation
affecting Ile500 has previously been reported in human
disease.
To explore the consequences of the identified mutations
on SMAD4 function, we performed structural analyses. We
observed that residues Asp493 and Arg497, which are
spatially close to Ile500 and are directly involved in inter-
subunit interactions in SMAD complexes, exhibit a signifi-
cant conformational flexibility in the available SMAD4
crystallographic structures (Figure S4). Interestingly, in
the structures of R-SMADs, where a Thr residue is found
at the position corresponding to Ile500, an orientation of
the residue corresponding to Arg497 pointing away from
the intersubunit interface is consistently observed
(Figure S4D). Substitution of Ile500 by Thr or Val in
SMAD4 is expected to weaken its hydrophobic interaction
with apolar atoms of the surrounding charged residues by
introducing a more hydrophilic and/or smaller side chain.
This is hypothesized to perturb the arrangement of their
side chains, which would affect proper function of the
SMAD heterotrimer. Of note, several observations indicate
that the region surrounding Ile500 is also critical for inter-
actions with other signaling partners. For instance, the
Arg496Ser and Arg502Ser substitutions have been shown
to impair the transcriptional activity of the complex
without affecting trimer formation.25 Therefore, it is
possible that the identified mutations might affect other
functionally relevant protein-protein interactions of the
mutant SMAD4. It is also of interest that, unlike R-SMADs,
SMAD4 is not regulated by reversible phosphorylation.
Instead, its function is controlled by monoubiquitina-
tion,26 which occurs at Lys519 and has been proposed to
sterically hamper the ability of the protein to form a stable
complex with activated R-SMADs, resulting in pathway
inhibition.27 On the basis of these considerations, it can
also be speculated that the subtle conformational change
promoted by the Myhre syndrome-causing amino acid
substitutions might impair proper SMAD4 ubiquitination
and perturb signal flow by increasing the intracellular
concentration of nonubiquitinylated SMAD4.166 The American Journal of Human Genetics 90, 161–169, January 1Detailed clinical information was obtained for all of the
subjects heterozygous for a SMAD4 mutation (Table 1).
Overall, these subjects presented with a homogeneous
phenotype (Figure 1A). Cardinal features of the syndrome,
including short stature (< third centile), a recognizable
facial appearance, generalized muscular hypertrophy,
hearing loss, short hands, distinctive skeletal anomalies,
and joint stiffness were observed in all individuals. All
subjects presented with low birth weight but five became
obese with age. Delayed psychomotor and/or language
development and variable intellectual disability was docu-
mented in all but one individual. One subject exhibited
noticeable psychological and behavioral issues. A wide
spectrum of congenital heart defects and skin anomalies
also recurred in the cohort, while macrocephaly, cleft lip
and/or palate, refractive errors, and hypertension were
less prevalent. Autistic behavior was documented in two
subjects. Of note, none of the eight subjects exhibited
any gross vascular anomaly or occurrence of skin, pancre-
atic, or gastrointestinal malignancies. Benign mesence-
phalic glioma and uncharacterized fibrous dysplasia of
the maxilla, however, were reported in one individual
(Table 1).
The TGFb signaling network controls a vast array of bio-
logical processes, including cell proliferation, differentia-
tion, apoptosis, adhesion, and lineage commitment, in
a cell type-dependent manner.28–30 The TGFb superfamily
of cytokines includes more than 30 structurally related
proteins belonging to the two major TGFb/activin and
BMP subfamilies.31 Among them, TGFb family members
play a diverse role in embryonic development,32,33 Simi-
larly, the members of the BMP family coordinate early
and late developmental processes, including tissue specifi-
cation, organogenesis, and skeletal pattering.34–37 Within
the TGFb/BMP signaling network, SMAD4 represents
a central node because it is required as a coactivator to
have transcriptionally active SMAD complexes.21 Based
on this crucial role, dysregulation of SMAD4 function is ex-
pected to have pleiotropic effects, which fits well with the
cardinal features of Myhre syndrome that result from
perturbation of several developmental pathways
controlled by TGFb/BMP signaling, including those
controlling axial and appendicular skeletal structures,
muscular tissue, and central nervous and cardiovascular
systems.
Germline mutations in SMAD4 are known to cause juve-
nile polyposis syndrome (JPS [MIM 174900]) and JPS-
hereditary hemorrhagic telangiectasia (JPS-HHT [MIM
175050]).38,39 The former is an autosomal-dominant
disorder usually diagnosed within the first decade of life
and characterized by hamartomatous polyps of the gastro-
intestinal tract and an increased risk of gastrointestinal
cancer.40 In the latter, the cancer-prone disease is associ-
ated with vascular dysplasia affectingmultiple organs, con-
sisting of telangiectases of the skin, oral and nasal mucosa,
and arteriovenous malformations of the lungs, liver, brain,
and gastrointestinal tract, which generally manifests by3, 2012
the fourth decade.41 JPS/JP-HHT causative SMAD4 muta-
tions are found throughout the gene and include
nonsense, missense, and splice-site changes, as well as
partial and complete gene deletions (Figure 1B and
Figure S2) (HGMD),42 supporting a loss-of-function model
of action. Consistent with this, loss of SMAD4 expression
or function due to somatic inactivating intragenic lesions
or gene deletions frequently occurs in carcinomas of the
pancreas, gastrointestinal tract, and skin (COSMIC). In
contrast, the invariant location and restricted spectrum
of Myhre syndrome-causative mutations support the idea
that these genetic lesions have distinct and specific conse-
quences on SMAD4 function. Although the characteriza-
tion of these mutants is required to appreciate the molec-
ular mechanism(s) implicated in perturbation of growth
and development driven by this previously unrecognized
class of SMAD4 mutants, structural analysis suggests that
they are likely to selectively interfere with the interaction
of the protein to signaling partners, possibly by perturbing
SMAD4 binding specificity and/or affinity.
Heterozygous missense SMAD4 mutations were identi-
fied in all affected subjects with Myhre syndrome included
in the study. This finding supports the idea that Myhre
syndrome is a genetically homogeneous disorder, or, at
minimum, that SMAD4 accounts for the preponderance
of cases. The restricted spectrum of mutations seems to
explain the relatively uniform phenotype characterizing
this disorder. On the basis of the different clinical outcome
of SMAD4mutations, however, it cannot be excluded that
additional, still unrecognized classes of gene variants
might underlie clinically related conditions, including
GOMBO syndrome, LAPS syndrome, Moore-Federman
syndrome, and mutation-negative GPHYSD and ACMICD.
Recent advances in targeted sequence capture and
massively parallel sequencing technologies offer new
opportunities for our understanding of themolecular bases
of Mendelian disorders,43,44 particularly those dramati-
cally influencing the fitness of affected individuals. Candi-
date gene filtering strategies based on the use of ontologies
of phenotypic features and cellular networks are predicted
to enhance the power of such unbiased approaches even
when coupled to the sequencing of single individuals
with rare diseases.Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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